Aca­dia un­veils the pos­i­tive PhI­II it's tak­ing to FDA for ex­pand­ing Nu­plazid's use in psy­chosis

Aca­dia Phar­ma­ceu­ti­cals has bro­ken out the num­bers prop­ping up Nu­plazid’s sur­prise ear­ly win in a Phase III de­men­tia study and, ac­cord­ing to one an­a­lyst, it’s “as good as we could have hoped for.”

The biotech stunned in­vestors three months ago when they an­nounced they’re halt­ing the HAR­MO­NY tri­al, hav­ing ob­tained enough pos­i­tive da­ta at an in­ter­im read­out to make a pitch to the FDA. It came as a sur­prise and stirred up a ral­ly around Aca­dia’s stock $ACAD, which has suf­fered from pre­vi­ous failed at­tempts at ex­pand­ing the con­tro­ver­sial Parkin­son’s dis­ease psy­chosis drug be­yond the ap­proved pa­tient pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER